Research programme: monoclonal antibody therapeutics - Trellis Bioscience/Open Monoclonal Technology
Latest Information Update: 21 Sep 2016
At a glance
- Originator Open Monoclonal Technology; Trellis Bioscience
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer; Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA (Parenteral)
- 09 Oct 2012 Early research in Cancer in USA (Parenteral)